Abstract
The vast majority of cancer deaths are the result of drug resistance. The lack of superior preclinical models that better reflect the complexity of relapsed disease hinders the development of novel therapeutics. 2D and 3D in vitro cell-based assays have provided some information, but this is limited and does not consider the role of the tumor microenvironment. The development of an in vivo assay can allow to generate resistance, while taking into account the role of the tumor microenvironment and the tumor structure. To achieve this, we have developed an in vivo dose-escalation protocol that models the acquisition of resistance. This model of chemo-resistant neuroblastoma presented with metastases and a genetic signature characteristic of clinical relapsed tumors (Yogev et al. Cancer Res. 79:5382–5393, 2019). We believe that this protocol can be used to generate faithful models for other types of relapse disease; these could serve as reliable tools while developing novel therapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mahvi DA et al (2018) Local cancer recurrence: the realities, challenges, and opportunities for new therapies. CA Cancer J Clin 68(6):488–505
Jin MZ, Jin WL (2020) The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther 5(1):166
Vasan N, Baselga J, Hyman DM (2019) A view on drug resistance in cancer. Nature 575(7782):299–309
Moreno L et al (2020) Accelerating drug development for neuroblastoma: summary of the second neuroblastoma drug development strategy forum from innovative therapies for children with cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer 136:52–68
Yogev O et al (2019) Modeling of Chemoresistant neuroblastoma provides new insights into Chemorefractory disease and metastasis. Cancer Res 79(20):5382–5393
Workman P et al (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102(11):1555–1577
McGrath JC et al (2010) Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160(7):1573–1576
Weiss WA et al (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16(11):2985–2995
Murciano-Goroff YR, Warner AB, Wolchok JD (2020) The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res 30(6):507–519
Chinnaswamy G et al (2011) Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. Eur J Cancer 47(10):1556–1563
Yoshida A et al (1993) Enhanced transcription of the cytosolic ALDH gene in cyclophosphamide resistant human carcinoma cells. Adv Exp Med Biol 328:63–72
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Barker, K.T., Yogev, O. (2022). Establishment of In Vivo Acquired Resistance to Chemotherapy Via Individual Dose Escalation Treatment Regime. In: Baiocchi, M. (eds) Cancer Drug Resistance. Methods in Molecular Biology, vol 2535. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2513-2_6
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2513-2_6
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2512-5
Online ISBN: 978-1-0716-2513-2
eBook Packages: Springer Protocols